Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

British Journal of Cancer

Volumn 78, Issue 1, 1998, Pages 34-39

  Chao, Y ^a   Chan, W K ^a   Birkhofer, M J ^d   Hu, O Y P ^b   Wang, S S ^a   Huang, Y S ^a   Liu, M ^c   Whang Peng, J ^c   Chi, K H ^a   Lui, W Y ^a   Lee, S D ^a,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d BRISTOL MYERS SQUIBB   (United States)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Hepatic function; Hepatocellular carcinoma; Paclitaxel; Pharmacokinetic

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GLUCOSE; PACLITAXEL;

ALLERGY; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MUCOSA INFLAMMATION; MYALGIA; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 7144257852     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.438     Document Type: Article

References (30)

1. Beahrs OH, Henson DE, Hutter RVP and Kennedy HJ (eds) (1992) Manual for Staging of Cancer. American Joint Committee Cancer, 4th edn. Lippincott: Philadelphia
2. Caesar J, Shaldon S and Chiandussi L (1961) The use of indocyanine green in the measurement of hepatic blood flow and as a lest of hepatic functions. Clin Sci 21: 43-57
3. Chan WK, Lin TH, Liu M, Chen YM, Wu MF and Whang-Peng J (1994) A pilot study of taxol treatment in carcinoma of unknown primary site: preliminary results. Therapeut Radiol Oncol 3: 217-227
4. Cherrick GR, Stein SW, Leevy CM and Davidson CS (1960) Indocyanine green: observation on its physical properties, plasma decay and hepatic extraction. J Clin Invest 39: 592-600
5. Farmen RH, Muniak JF and Pittman KA (1987) Management of pharmacokinetic data using HP-3357/mainframe IBM interfacing. Drug Information J 21: 141-152
6. Gianni L, Capri G, Munzone E and Straneo M (1994) Paclitaxel (taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 21(S8): 29-33
7. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W and Brodeur GM (1989) Expression of a multiple drug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124
8. Guastalla JP, Lhomme C, Dauplat J, Namer M, Bonneterre J, Oberling F, Pouillart P, Fumoleau P, Kerbrat P and Tubiana N (1994) Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study. Ann Oncol 5(S6): S33-38
9. Guchelaar HJ, ten Napel CH, de Vries EG and Mulder NH (1994) Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol 6: 40-48
10. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ and Yang CP (1993) Taxol: mechanisms of action and resistance. M Natl Cancer Inst 15: 55-61
11. Jamis-Dow CA, Klecker RW, Katki AG and Collins JM (1995) Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 6: 107-114
12. Jwo SC, Chiu JH, Vhan GGY, Loong CC and Lui WY (1992) Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 16: 1367-1371
13. Kaplan EM and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statis Assoc 53: 457-481
14. Lai KH, Tsai YT, Lee SD, Ng WW, Teng HC, Tam TN, Lo GH, Lin HC, Lin HJ, Wu JC, Lay CS, Wang SS and Chan WK (1989) Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol 23: 54-56
15. Muir C (1989) Cancer Incidence in Five Continents. IARC: Lyons France
16. Okamoto E, Kyo A, Yamanaka N, Tanaka N and Kuwata K (1984) Prediction of the safe limit of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery 95: 586-592
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
18. Riegelman S and Collier P (1984) An application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmaco Biopharm 8: 509-534
19. Rowinsky EK (1994) Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmaco 28(S): S18-22
20. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ and Donehower RC (1993a) Taxol: pharmacology, metabolism and clinical implications. Cancer Surv 17: 283-304
21. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG and Donehower RS (1993b) Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 20(S3): 1-15
22. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
23. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ and Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532-538
24. Tong MJ, Sun SC, Schaeffer BT, Chang NK, Lo KJ and Peters RL (1971) Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med 75: 687-691
25. Venook AP (1994a) Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12: 1323-1334
26. Venook AP, Egorin M, Brown TD, Batist G, Budman DR, Rosner GL, Jahan TM and Schilsky RL (1994b) Paclitaxel (taxol) in patients with liver dysfunction. Proc Am Soc Clin Oncol 13: A350
27. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J and Woodcock D (1993) Measurement of cremophor EL following taxol: plasma level sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85: 1685-1690
28. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH and Farman RH (1993) High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621: 231-238
29. Wilson WH, Berg SL, Bryant G, Wittes RE, Butes S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J and O'Shaughnessy J (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 12: 1621-1629
30. Wu CC, Ho WL, Yeh DC, Huang CR, Liu TJ and P'eng FK (1996) Hepatic resection of hepatocellular carcinoma in cirrhotic liver: is it unjustified in impaired liver function? Surgery 120: 34-39